We have identi®ed a novel cytoskeletal protein, EPLIN (Epithelial Protein Lost In Neoplasm) , that is preferentially expressed in human epithelial cells. Two EPLIN isoforms, a 600 amino acid EPLIN-a and a 759 amino acid EPLIN-b, are detected in primary epithelial cells of oral mucosa, prostate and mammary glands. The expression of EPLIN-a is either down-regulated or lost in the majority of oral cancer cell lines (8/8), prostate cancer cell lines (4/4) and xenograft tumors (3/3), and breast cancer cell lines (5/6). The amino acid sequence of EPLIN is characterized by the presence of a single centrally located LIM domain. Both EPLIN isoforms localize to ®lamentous actin and suppress cell proliferation when overexpressed. These ®ndings indicate that the loss of EPLIN seen in cancer cells may play a role in cancer progression.
Keywords: breast; prostate; cancer; EPLIN Most genes mutated in cancer are involved primarily in the maintenance of genomic integrity (Lengauer et al., 1998) and the control of cell cycle progression (Sherr, 1998) . These mutations in turn aect expression of a larger number of cellular genes which collectively are responsible for the changes in cell phenotype. Recent gene expression analyses have indicated that roughly 1 ± 2% of the 10 000 ± 15 000 genes expressed in a given cell type are dierentially expressed in cancer cells when compared to the normal cells (Liang and Pardee, 1995; Zhang et al., 1997) . Using a PCR-based representational dierence analysis, we conducted an analysis of gene expression comparing normal human oral keratinocytes (NHOK) to their transformed counterparts (Chang et al., 1998) . One of the cDNA fragments (Clone 21) corresponding to a gene that is preferentially expressed in NHOK contained a partial open reading frame (ORF) characterized by the presence of a LIM domain. The LIM domain is a putative protein ± protein interaction domain capable of forming two closely spaced zinc-binding subdomains (Perez-Alvarado et al., 1994) . Many LIM domain proteins participate in cell dierentiation, as components of transcription machinery (Dawid et al., 1998; Jurata and Gill, 1998) . LIM domains are also frequently found in cytoskeletal proteins (Brown et al., 1996; Beckerle, 1997) .
Clone 21 was used as a probe to isolate cDNA clones from a HeLa cell library. Sequence analysis allowed us to assemble an ORF of 600 aa (EPLIN-a) and an isoform (EPLIN-b) that extended an additional 160 aa at the amino terminus (Figure 1a,b) . Southern analysis indicated that EPLIN is a single copy gene (data not shown), suggesting that the two EPLIN isoforms are generated by an alternative pre-RNA processing event. The predicted amino acid sequence of EPLIN was notable for a single centrally located LIM domain that is homologous to the partial ORF of an unknown hamster gene that was previously identi®ed as a fusion partner of the sterol response element binding protein in a sterol-resistant hamster cell line SRD-2 (Yang et al., 1995) . Beside this homology, the EPLIN LIM domain is distantly related to the LIM domains of plant transcription factor SF-3 and the muscle LIM protein (Figure 1c) .
Northern blot analysis of poly(A) + -RNA derived from normal human adult tissues demonstrated the expression of two EPLIN transcripts of *3.8 kb and *8 kb in size (Figure 2a) . The highest level of EPLIN mRNA was observed in placenta, followed by kidney, pancreas, prostate, ovary, spleen, and heart. A low level of EPLIN mRNA was also detected in all other tissues. The ORFs for both EPLIN-a and b can be assembled from cDNA clones with insert sizes of *3.6 kb, corresponding to the *3.8 kb transcript seen on the Northern. The identity of *8 kb transcript, which could represent an alternatively processed mRNA or a product of a closely related gene, is not known. We have not been able to detect a similar *8 kb transcript in most cell cultures (data not shown). Since the immunoblot analysis revealed only two polypeptides of 90 kD and 110 kD (see below), corresponding to the EPLIN-a and -b isoforms predicted from the sequencing of the cloned cDNAs, the *8 kb transcript was not further characterized in this study.
In normal primary mammary (MEC), prostate (PrEC), and oral (NHOK) epithelial cells, anti-EPLIN antisera detected a major protein band of 90 kD and a second minor species of 110 kD ( Figure 2b ). Using lysates prepared from the cells transfected with EPLIN-a and EPLIN-b cDNA, we were able to assign these two species as EPLIN-a and EPLIN-b, respectively (data not shown). Low levels of EPLIN were also detected in the primary aortic endothelial cells and dermal ®broblasts, but not in the myocardium. The absence of EPLIN proteins in the myocardium, in view of the relative abundance of EPLIN transcripts in the same tissue, suggests that the steady state level of EPLIN proteins can be subjected to a posttranslational regulation.
A Northern analysis of immortalized or transformed oropharyngeal cell lines con®rmed a consistent downregulation of EPLIN transcripts to 10 ± 60% of the level seen in the NHOK (Figure 3a ). An immunoblot analysis demonstrated a reduction in EPLIN protein in these cell lines (data not shown). Using anti-EPLIN antisera, we extended the expression analysis of EPLIN in dierent types of human cancers. In two PSA-negative prostate cancer cell lines, PC3 and DU145, EPLIN expression was detectable, but at signi®cantly reduced levels compared to the level seen in the PrEC (Figure 3b ). In two PSA-positive prostate cancer cell lines, LnCap and LAPC4 (Klein et al., 1997) , the expression of EPLIN-a was not detectable, while EPLIN-b continued to be expressed at a level comparable to that in the PrEC. Examination of human prostate tumors propogated in SCID mice also demonstrated the loss of EPLIN-a expression in LAPC3, LAPC4, and LAPC9 xenografts (Klein et al., 1997) . A survey of breast cancer cell lines revealed a similar change in EPLIN expression ( Figure  3c ). Both immortalized mammary epithelial cells (IMEC) and HBL-100, a non-tumorigenic breast cancer cell line, expressed EPLIN-a and -b isoforms at levels equivalent to that seen in the MEC. In the BT-20 breast cancer cells, there was a reduction in EPLIN-a accompanied by an increase in EPLIN-b. A similar increase EPLIN-b expression was also seen in the SKBr-3 breast cancer cells which lacked the EPLIN-a expression. It should be noted that, despite the increase in EPLIN-b, the combined levels of the two EPLIN isoforms were lower in BT-20 and SK-Br-3 cells. In three other breast cancer cell lines. EPLIN-a was either absent (MCF-7 and T-47D) or signi®cantly reduced (MDA-MB-231), while EPLIN-b continued to be expressed at a level equivalent to that in the MEC. A Northern analysis demonstrated a reduction in EPLIN transcripts in all of the breast cancer cell lines, con®rming that the loss of EPLIN proteins is due to a transcriptional down-regulation (Figure 3d ).
To investigate the potential function of EPLIN, we ®rst determined the subcellular distribution of endogenous EPLIN. Since the available polyclonal anti-EPLIN antisera do not distinguish the two known isoforms of EPLIN, we carried out in situ immunouorescence using two dierent cell lines, HOK18C (an immortalized human oral keratinocyte line), and BeWo (a human choriocarcinoma cell line). EPLIN-a is expressed as the predominant form of HOK18C, (Nagase et al., 1998) , plant transcription factor SF3 (Baltz et al., 1992) , and muscle LIM protein (Arber et al., 1994) is shown. The signature cysteine and histidine residues of LIM domain are indicated by bold lettering. Amino acid sequence identities (.) and similarities (underlined) are indicated while EPLIN-b is the predominant form in BeWo (Figure 4a) . In situ immuno¯uorescence analysis demonstrated the localization of both EPLIN-a and -b to the cytoplasm in a ®brillar pattern at the periphery of the cell (Figure 4b,d ). This pattern of staining is similar to the staining of actin ®bers with phalloidin (Figure 4c,e) . Furthermore, there was a frequent overlap between EPLIN staining and paxillin staining (data not shown), suggesting that EPLIN maybe present in the focal adhesion plaques as well.
To study the eect of EPLIN on cell growth, we expressed each isoform in U2-OS osteosarcoma cells under the control of a tetracycline-inducible promoter. US-OS cells, like most other cells, express EPLIN-a as the major isoform and a small amount of EPLIN-b isoform (Figure 5e ). Ectopic expression of either EPLIN isoform altered the morphology of the U2-OS cells from round polygonal cells with a cobblestone appearance to larger fusiform cells with spindle cell features and cytoplasmic extensions (Figure 5a ± d) . In addition, the HOK18C and BeWo cells cultured on ®bronectin-coated glass coverslips for 18 h were ®xed in 3.7% formaldehyde in PBS for 10 min and permeabilized in 0.2% Triton X-100 in PBS for 5 min. The slides were preincubated in a blocking buer (0.1% Tween-20+10% goat serum in PBS) for 30 min before the addition of polyclonal anti-EPLIN antibodies (1 : 200 dilution). Coverslips were mounted with ProLong Antifade (Molecular Probes) and viewed under a¯uorescence microscope. Pre-immune sera did not produce a staining pattern EPLIN overexpressing cells required a longer incubation time in trypsin for detachment (data not shown), suggesting a change in the cell-matrix interaction. An analysis of cell proliferation using a tetrazolium dye inclusion assay revealed that the induction of EPLIN-b suppresses cell growth (Figure 5f ). While the eect was not as pronounced, a growth inhibition was also seen when EPLIN-a was overexpressed. The lack of a signi®cant growth suppression by EPLIN-a in the U2-OS cells, however, should be interpreted with caution since the US-OS cells express a higher level of endogenous EPLIN-a than EPLIN-b. It will be interesting to investigate how ectopic expression of EPLIN-a aects the growth of cells such as MCF-7 or LnCap that lack endogenous EPLIN-a.
Based on the ®ndings presented in this study, we conclude that EPLIN is a cytoskeletal protein that is preferentially expressed in epithelial cells. The expression of EPLIN is down-regulated in the majority of oral (8/8), prostate (7/7) and breast (5/6) cancer cells. The overexpression of EPLIN results in growth suppression, suggesting that EPLIN functions as a tumor suppressor. Many cancer cells display abnormal cell-matrix interactions and can proliferate in the absence of cell-matrix interaction. It will be interesting to further explore the relationship between the loss of EPLIN and abnormal cell proliferation and migration, events that are commonly associated with progression of cancer in humans. (Denizot and Lang, 1986) 
